JP2011528367A - 二酸化塩素により口腔感染症を治療する方法 - Google Patents
二酸化塩素により口腔感染症を治療する方法 Download PDFInfo
- Publication number
- JP2011528367A JP2011528367A JP2011518869A JP2011518869A JP2011528367A JP 2011528367 A JP2011528367 A JP 2011528367A JP 2011518869 A JP2011518869 A JP 2011518869A JP 2011518869 A JP2011518869 A JP 2011518869A JP 2011528367 A JP2011528367 A JP 2011528367A
- Authority
- JP
- Japan
- Prior art keywords
- chlorine dioxide
- composition
- tissue
- oxychlorine
- source
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- OSVXSBDYLRYLIG-UHFFFAOYSA-N dioxidochlorine(.) Chemical compound O=Cl=O OSVXSBDYLRYLIG-UHFFFAOYSA-N 0.000 title claims abstract description 625
- 239000004155 Chlorine dioxide Substances 0.000 title claims abstract description 313
- 235000019398 chlorine dioxide Nutrition 0.000 title claims abstract description 313
- 206010048685 Oral infection Diseases 0.000 title description 8
- 239000000203 mixture Substances 0.000 claims abstract description 195
- 238000000034 method Methods 0.000 claims abstract description 79
- 208000015181 infectious disease Diseases 0.000 claims abstract description 28
- 150000001450 anions Chemical class 0.000 claims description 114
- 230000004888 barrier function Effects 0.000 claims description 82
- 239000000463 material Substances 0.000 claims description 70
- -1 polypropylene Polymers 0.000 claims description 63
- 239000011159 matrix material Substances 0.000 claims description 52
- 231100000065 noncytotoxic Toxicity 0.000 claims description 37
- 230000002020 noncytotoxic effect Effects 0.000 claims description 37
- 231100000344 non-irritating Toxicity 0.000 claims description 21
- 229920001343 polytetrafluoroethylene Polymers 0.000 claims description 21
- 239000004810 polytetrafluoroethylene Substances 0.000 claims description 21
- 239000002243 precursor Substances 0.000 claims description 17
- 210000000214 mouth Anatomy 0.000 claims description 14
- 239000004814 polyurethane Substances 0.000 claims description 12
- 229920002635 polyurethane Polymers 0.000 claims description 12
- 201000001245 periodontitis Diseases 0.000 claims description 11
- 229920002981 polyvinylidene fluoride Polymers 0.000 claims description 11
- 239000004743 Polypropylene Substances 0.000 claims description 10
- 239000004599 antimicrobial Substances 0.000 claims description 10
- 229920001155 polypropylene Polymers 0.000 claims description 10
- 229920001296 polysiloxane Polymers 0.000 claims description 10
- 229920001328 Polyvinylidene chloride Polymers 0.000 claims description 9
- 208000002925 dental caries Diseases 0.000 claims description 9
- 208000007565 gingivitis Diseases 0.000 claims description 9
- 206010006326 Breath odour Diseases 0.000 claims description 8
- 239000004793 Polystyrene Substances 0.000 claims description 8
- 229920002301 cellulose acetate Polymers 0.000 claims description 8
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 8
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 8
- 229920002223 polystyrene Polymers 0.000 claims description 8
- 229920000058 polyacrylate Polymers 0.000 claims description 7
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 claims description 6
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 claims description 6
- 229930183010 Amphotericin Natural products 0.000 claims description 6
- QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 claims description 6
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 claims description 6
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 claims description 6
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 6
- 239000004098 Tetracycline Substances 0.000 claims description 6
- 229940009444 amphotericin Drugs 0.000 claims description 6
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 claims description 6
- 239000003242 anti bacterial agent Substances 0.000 claims description 6
- 229960003260 chlorhexidine Drugs 0.000 claims description 6
- 238000011161 development Methods 0.000 claims description 6
- 229960003722 doxycycline Drugs 0.000 claims description 6
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims description 6
- 229960000282 metronidazole Drugs 0.000 claims description 6
- 229960002509 miconazole Drugs 0.000 claims description 6
- 229960004023 minocycline Drugs 0.000 claims description 6
- 229960000988 nystatin Drugs 0.000 claims description 6
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 claims description 6
- 239000012188 paraffin wax Substances 0.000 claims description 6
- 229960002180 tetracycline Drugs 0.000 claims description 6
- 229930101283 tetracycline Natural products 0.000 claims description 6
- 235000019364 tetracycline Nutrition 0.000 claims description 6
- 150000003522 tetracyclines Chemical class 0.000 claims description 6
- 206010011224 Cough Diseases 0.000 claims description 5
- 229920002367 Polyisobutene Polymers 0.000 claims description 5
- 239000002480 mineral oil Substances 0.000 claims description 5
- 235000010446 mineral oil Nutrition 0.000 claims description 5
- 229920001083 polybutene Polymers 0.000 claims description 5
- 208000032139 Halitosis Diseases 0.000 claims description 4
- 210000001519 tissue Anatomy 0.000 description 107
- 239000000243 solution Substances 0.000 description 51
- 239000010410 layer Substances 0.000 description 46
- 239000012530 fluid Substances 0.000 description 39
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 35
- 230000002378 acidificating effect Effects 0.000 description 24
- 229910052736 halogen Inorganic materials 0.000 description 20
- 150000002367 halogens Chemical class 0.000 description 18
- 239000002562 thickening agent Substances 0.000 description 18
- 238000011282 treatment Methods 0.000 description 18
- 230000002209 hydrophobic effect Effects 0.000 description 17
- 239000000126 substance Substances 0.000 description 17
- 239000007787 solid Substances 0.000 description 16
- 238000004519 manufacturing process Methods 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 239000008187 granular material Substances 0.000 description 14
- 239000004615 ingredient Substances 0.000 description 14
- 239000000460 chlorine Substances 0.000 description 13
- 229910001919 chlorite Inorganic materials 0.000 description 13
- 229910052619 chlorite group Inorganic materials 0.000 description 13
- QBWCMBCROVPCKQ-UHFFFAOYSA-N chlorous acid Chemical compound OCl=O QBWCMBCROVPCKQ-UHFFFAOYSA-N 0.000 description 13
- UKLNMMHNWFDKNT-UHFFFAOYSA-M sodium chlorite Chemical compound [Na+].[O-]Cl=O UKLNMMHNWFDKNT-UHFFFAOYSA-M 0.000 description 13
- 229960002218 sodium chlorite Drugs 0.000 description 13
- 239000012736 aqueous medium Substances 0.000 description 12
- 239000012528 membrane Substances 0.000 description 12
- 210000004379 membrane Anatomy 0.000 description 12
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 11
- 229910052801 chlorine Inorganic materials 0.000 description 11
- 229910052751 metal Inorganic materials 0.000 description 11
- 239000002184 metal Substances 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- XTEGARKTQYYJKE-UHFFFAOYSA-M Chlorate Chemical compound [O-]Cl(=O)=O XTEGARKTQYYJKE-UHFFFAOYSA-M 0.000 description 10
- 239000003054 catalyst Substances 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 239000003814 drug Substances 0.000 description 9
- 239000007789 gas Substances 0.000 description 9
- 239000011148 porous material Substances 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 230000003013 cytotoxicity Effects 0.000 description 8
- 231100000135 cytotoxicity Toxicity 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 210000004872 soft tissue Anatomy 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 239000000416 hydrocolloid Substances 0.000 description 7
- 230000007794 irritation Effects 0.000 description 7
- 235000019271 petrolatum Nutrition 0.000 description 7
- 229920000642 polymer Polymers 0.000 description 7
- 239000002994 raw material Substances 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 238000009792 diffusion process Methods 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 238000011065 in-situ storage Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- 229940121375 antifungal agent Drugs 0.000 description 5
- 239000002131 composite material Substances 0.000 description 5
- 230000002500 effect on skin Effects 0.000 description 5
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 5
- 239000012982 microporous membrane Substances 0.000 description 5
- 230000007935 neutral effect Effects 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 244000052769 pathogen Species 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 210000003296 saliva Anatomy 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 239000011343 solid material Substances 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- 229920006347 Elastollan Polymers 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 239000012190 activator Substances 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- QBWCMBCROVPCKQ-UHFFFAOYSA-M chlorite Chemical compound [O-]Cl=O QBWCMBCROVPCKQ-UHFFFAOYSA-M 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 210000002200 mouth mucosa Anatomy 0.000 description 4
- 239000007800 oxidant agent Substances 0.000 description 4
- 230000020477 pH reduction Effects 0.000 description 4
- 239000011236 particulate material Substances 0.000 description 4
- 208000028169 periodontal disease Diseases 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000002356 single layer Substances 0.000 description 4
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 4
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 4
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 4
- 238000004448 titration Methods 0.000 description 4
- 239000001993 wax Substances 0.000 description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 208000025157 Oral disease Diseases 0.000 description 3
- 239000004264 Petrolatum Substances 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 229910052783 alkali metal Inorganic materials 0.000 description 3
- 238000004082 amperometric method Methods 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 208000030194 mouth disease Diseases 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 231100000017 mucous membrane irritation Toxicity 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 235000019809 paraffin wax Nutrition 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 229940066842 petrolatum Drugs 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000036556 skin irritation Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 241000416162 Astragalus gummifer Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000144583 Candida dubliniensis Species 0.000 description 2
- 241000195493 Cryptophyta Species 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 241000605986 Fusobacterium nucleatum Species 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 2
- 241001135235 Tannerella forsythia Species 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 241000589892 Treponema denticola Species 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000002998 adhesive polymer Substances 0.000 description 2
- 230000002353 algacidal effect Effects 0.000 description 2
- 230000000843 anti-fungal effect Effects 0.000 description 2
- 230000003610 anti-gingivitis Effects 0.000 description 2
- 230000002882 anti-plaque Effects 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 238000004061 bleaching Methods 0.000 description 2
- 230000005587 bubbling Effects 0.000 description 2
- CXKCTMHTOKXKQT-UHFFFAOYSA-N cadmium oxide Inorganic materials [Cd]=O CXKCTMHTOKXKQT-UHFFFAOYSA-N 0.000 description 2
- CFEAAQFZALKQPA-UHFFFAOYSA-N cadmium(2+);oxygen(2-) Chemical compound [O-2].[Cd+2] CFEAAQFZALKQPA-UHFFFAOYSA-N 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000004927 clay Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 210000003298 dental enamel Anatomy 0.000 description 2
- 210000004268 dentin Anatomy 0.000 description 2
- 230000001877 deodorizing effect Effects 0.000 description 2
- 230000000249 desinfective effect Effects 0.000 description 2
- CEJLBZWIKQJOAT-UHFFFAOYSA-N dichloroisocyanuric acid Chemical compound ClN1C(=O)NC(=O)N(Cl)C1=O CEJLBZWIKQJOAT-UHFFFAOYSA-N 0.000 description 2
- HTXDPTMKBJXEOW-UHFFFAOYSA-N dioxoiridium Chemical compound O=[Ir]=O HTXDPTMKBJXEOW-UHFFFAOYSA-N 0.000 description 2
- GNTDGMZSJNCJKK-UHFFFAOYSA-N divanadium pentaoxide Chemical compound O=[V](=O)O[V](=O)=O GNTDGMZSJNCJKK-UHFFFAOYSA-N 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 230000000855 fungicidal effect Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
- PJXISJQVUVHSOJ-UHFFFAOYSA-N indium(iii) oxide Chemical compound [O-2].[O-2].[O-2].[In+3].[In+3] PJXISJQVUVHSOJ-UHFFFAOYSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 229940094522 laponite Drugs 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- XCOBTUNSZUJCDH-UHFFFAOYSA-B lithium magnesium sodium silicate Chemical compound [Li+].[Li+].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Na+].[Na+].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3 XCOBTUNSZUJCDH-UHFFFAOYSA-B 0.000 description 2
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229910044991 metal oxide Inorganic materials 0.000 description 2
- 150000004706 metal oxides Chemical class 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229920000620 organic polymer Polymers 0.000 description 2
- RVTZCBVAJQQJTK-UHFFFAOYSA-N oxygen(2-);zirconium(4+) Chemical compound [O-2].[O-2].[Zr+4] RVTZCBVAJQQJTK-UHFFFAOYSA-N 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- 238000005373 pervaporation Methods 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920006264 polyurethane film Polymers 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- WOCIAKWEIIZHES-UHFFFAOYSA-N ruthenium(iv) oxide Chemical compound O=[Ru]=O WOCIAKWEIIZHES-UHFFFAOYSA-N 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 150000003464 sulfur compounds Chemical class 0.000 description 2
- XOLBLPGZBRYERU-UHFFFAOYSA-N tin dioxide Chemical compound O=[Sn]=O XOLBLPGZBRYERU-UHFFFAOYSA-N 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- ZNOKGRXACCSDPY-UHFFFAOYSA-N tungsten trioxide Chemical compound O=[W](=O)=O ZNOKGRXACCSDPY-UHFFFAOYSA-N 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 229910001928 zirconium oxide Inorganic materials 0.000 description 2
- YRIZYWQGELRKNT-UHFFFAOYSA-N 1,3,5-trichloro-1,3,5-triazinane-2,4,6-trione Chemical compound ClN1C(=O)N(Cl)C(=O)N(Cl)C1=O YRIZYWQGELRKNT-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 241000606750 Actinobacillus Species 0.000 description 1
- 241000186044 Actinomyces viscosus Species 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- ZKQDCIXGCQPQNV-UHFFFAOYSA-N Calcium hypochlorite Chemical compound [Ca+2].Cl[O-].Cl[O-] ZKQDCIXGCQPQNV-UHFFFAOYSA-N 0.000 description 1
- 241000589996 Campylobacter rectus Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 208000002064 Dental Plaque Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- 241000588878 Eikenella corrodens Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 241000186394 Eubacterium Species 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000544 Gore-Tex Polymers 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- RAXXELZNTBOGNW-UHFFFAOYSA-O Imidazolium Chemical compound C1=C[NH+]=CN1 RAXXELZNTBOGNW-UHFFFAOYSA-O 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 238000002768 Kirby-Bauer method Methods 0.000 description 1
- 208000034693 Laceration Diseases 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- 241000187654 Nocardia Species 0.000 description 1
- 206010061324 Oral fungal infection Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 241000605894 Porphyromonas Species 0.000 description 1
- 241000605862 Porphyromonas gingivalis Species 0.000 description 1
- 241000605861 Prevotella Species 0.000 description 1
- 241001135221 Prevotella intermedia Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000019802 Sexually transmitted disease Diseases 0.000 description 1
- 208000001203 Smallpox Diseases 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- 241000589970 Spirochaetales Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000194019 Streptococcus mutans Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 239000004433 Thermoplastic polyurethane Substances 0.000 description 1
- 208000008312 Tooth Loss Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 241000870995 Variola Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- WOHVONCNVLIHKY-UHFFFAOYSA-L [Ba+2].[O-]Cl=O.[O-]Cl=O Chemical compound [Ba+2].[O-]Cl=O.[O-]Cl=O WOHVONCNVLIHKY-UHFFFAOYSA-L 0.000 description 1
- QDMGKUOANLJICG-UHFFFAOYSA-N [Mg].[N+](=O)(O)[O-] Chemical compound [Mg].[N+](=O)(O)[O-] QDMGKUOANLJICG-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 description 1
- 238000003928 amperometric titration Methods 0.000 description 1
- 150000001449 anionic compounds Chemical class 0.000 description 1
- 230000001098 anti-algal effect Effects 0.000 description 1
- 230000002272 anti-calculus Effects 0.000 description 1
- 230000000170 anti-cariogenic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000012431 aqueous reaction media Substances 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229960000892 attapulgite Drugs 0.000 description 1
- JRPBQTZRNDNNOP-UHFFFAOYSA-N barium titanate Chemical compound [Ba+2].[Ba+2].[O-][Ti]([O-])([O-])[O-] JRPBQTZRNDNNOP-UHFFFAOYSA-N 0.000 description 1
- 229910002113 barium titanate Inorganic materials 0.000 description 1
- PQRDTUFVDILINV-UHFFFAOYSA-N bcdmh Chemical compound CC1(C)N(Cl)C(=O)N(Br)C1=O PQRDTUFVDILINV-UHFFFAOYSA-N 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 229940092782 bentonite Drugs 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 230000001680 brushing effect Effects 0.000 description 1
- 210000005178 buccal mucosa Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- AOWKSNWVBZGMTJ-UHFFFAOYSA-N calcium titanate Chemical compound [Ca+2].[O-][Ti]([O-])=O AOWKSNWVBZGMTJ-UHFFFAOYSA-N 0.000 description 1
- WEUCVIBPSSMHJG-UHFFFAOYSA-N calcium titanate Chemical compound [O-2].[O-2].[O-2].[Ca+2].[Ti+4] WEUCVIBPSSMHJG-UHFFFAOYSA-N 0.000 description 1
- QXIKMJLSPJFYOI-UHFFFAOYSA-L calcium;dichlorite Chemical compound [Ca+2].[O-]Cl=O.[O-]Cl=O QXIKMJLSPJFYOI-UHFFFAOYSA-L 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 150000001793 charged compounds Chemical class 0.000 description 1
- 229910052729 chemical element Inorganic materials 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000003711 chorioallantoic membrane Anatomy 0.000 description 1
- 229940117975 chromium trioxide Drugs 0.000 description 1
- WGLPBDUCMAPZCE-UHFFFAOYSA-N chromium trioxide Inorganic materials O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 description 1
- GAMDZJFZMJECOS-UHFFFAOYSA-N chromium(6+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[Cr+6] GAMDZJFZMJECOS-UHFFFAOYSA-N 0.000 description 1
- 208000034391 chronic adult periodontitis Diseases 0.000 description 1
- 208000001277 chronic periodontitis Diseases 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- LBJNMUFDOHXDFG-UHFFFAOYSA-N copper;hydrate Chemical compound O.[Cu].[Cu] LBJNMUFDOHXDFG-UHFFFAOYSA-N 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- VRLDVERQJMEPIF-UHFFFAOYSA-N dbdmh Chemical compound CC1(C)N(Br)C(=O)N(Br)C1=O VRLDVERQJMEPIF-UHFFFAOYSA-N 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000007799 dermal corrosion Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 229920000295 expanded polytetrafluoroethylene Polymers 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012527 feed solution Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- CJNBYAVZURUTKZ-UHFFFAOYSA-N hafnium(iv) oxide Chemical compound O=[Hf]=O CJNBYAVZURUTKZ-UHFFFAOYSA-N 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 229920001903 high density polyethylene Polymers 0.000 description 1
- 239000004700 high-density polyethylene Substances 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 238000009863 impact test Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910001412 inorganic anion Inorganic materials 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- LIKBJVNGSGBSGK-UHFFFAOYSA-N iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[Fe+3].[Fe+3] LIKBJVNGSGBSGK-UHFFFAOYSA-N 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 229920001684 low density polyethylene Polymers 0.000 description 1
- 239000004702 low-density polyethylene Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- NWAPVVCSZCCZCU-UHFFFAOYSA-L magnesium;dichlorite Chemical compound [Mg+2].[O-]Cl=O.[O-]Cl=O NWAPVVCSZCCZCU-UHFFFAOYSA-L 0.000 description 1
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910001463 metal phosphate Inorganic materials 0.000 description 1
- 229910052976 metal sulfide Inorganic materials 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000012229 microporous material Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- ZKATWMILCYLAPD-UHFFFAOYSA-N niobium pentoxide Inorganic materials O=[Nb](=O)O[Nb](=O)=O ZKATWMILCYLAPD-UHFFFAOYSA-N 0.000 description 1
- URLJKFSTXLNXLG-UHFFFAOYSA-N niobium(5+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[O-2].[Nb+5].[Nb+5] URLJKFSTXLNXLG-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- BPUBBGLMJRNUCC-UHFFFAOYSA-N oxygen(2-);tantalum(5+) Chemical compound [O-2].[O-2].[O-2].[O-2].[O-2].[Ta+5].[Ta+5] BPUBBGLMJRNUCC-UHFFFAOYSA-N 0.000 description 1
- 229910052625 palygorskite Inorganic materials 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000003239 periodontal effect Effects 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- XYFCBTPGUUZFHI-UHFFFAOYSA-O phosphonium Chemical compound [PH4+] XYFCBTPGUUZFHI-UHFFFAOYSA-O 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 230000002186 photoactivation Effects 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000012667 polymer degradation Methods 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 1
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 1
- SATVIFGJTRRDQU-UHFFFAOYSA-N potassium hypochlorite Chemical compound [K+].Cl[O-] SATVIFGJTRRDQU-UHFFFAOYSA-N 0.000 description 1
- VISKNDGJUCDNMS-UHFFFAOYSA-M potassium;chlorite Chemical compound [K+].[O-]Cl=O VISKNDGJUCDNMS-UHFFFAOYSA-M 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical compound C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- VFWRGKJLLYDFBY-UHFFFAOYSA-N silver;hydrate Chemical compound O.[Ag].[Ag] VFWRGKJLLYDFBY-UHFFFAOYSA-N 0.000 description 1
- 231100000108 skin corrosion Toxicity 0.000 description 1
- 229910021647 smectite Inorganic materials 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- PYILKOIEIHHYGD-UHFFFAOYSA-M sodium;1,5-dichloro-4,6-dioxo-1,3,5-triazin-2-olate;dihydrate Chemical compound O.O.[Na+].[O-]C1=NC(=O)N(Cl)C(=O)N1Cl PYILKOIEIHHYGD-UHFFFAOYSA-M 0.000 description 1
- 210000001584 soft palate Anatomy 0.000 description 1
- 239000011973 solid acid Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- VEALVRVVWBQVSL-UHFFFAOYSA-N strontium titanate Chemical compound [Sr+2].[O-][Ti]([O-])=O VEALVRVVWBQVSL-UHFFFAOYSA-N 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-O sulfonium Chemical compound [SH3+] RWSOTUBLDIXVET-UHFFFAOYSA-O 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229920000247 superabsorbent polymer Polymers 0.000 description 1
- 239000004583 superabsorbent polymers (SAPs) Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 239000004758 synthetic textile Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229920002803 thermoplastic polyurethane Polymers 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 230000009974 thixotropic effect Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 238000013334 tissue model Methods 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 239000002351 wastewater Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
- VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/20—Halogens; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/20—Halogens; Compounds thereof
- A61K8/21—Fluorides; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0063—Periodont
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
Abstract
【選択図】なし
Description
本出願は、それぞれの全内容が参照により本明細書に組み込まれている、2008年7月15日出願の米国仮特許出願第61/135011号、2008年10月16日出願の第61/106026号、2009年2月6日出願の第61/150685号および2009年6月15日出願の第61/187198号についての合衆国法典第35巻第119条(e)に基づく利益を請求する。
特に定義しない限り、本明細書で使用する全ての技術的および科学的用語は、一般的に当業者によって理解されるのと同じ意味を有する。一般的に、本明細書で使用する命名法、ならびに細胞壊死性分析、微生物分析、有機および無機化学、および歯科臨床的研究における検査法は、当技術分野で周知であり一般に使用されているものである。
二酸化塩素は、十分に裏付けられた強力な殺生物活性を有する。不都合なことに、先行技術の二酸化塩素含有組成物は、細胞毒性であり、軟組織を刺激し、硬組織に損傷を与える可能性がある。二酸化塩素含有組成物の細胞毒性は、主としてオキシ塩素アニオンの存在から生じ、二酸化塩素分解産物である可能性がある塩素の存在から生じるのではない。二酸化塩素含有組成物中に存在するオキシ塩素アニオンが、治療の標的にされるエナメル質および象牙質などの硬い歯の組織ならびに口腔粘膜および歯肉などの軟らかい口腔組織を含む細胞および組織と接触するのを実質的に防止する、または阻害することにより、組織損傷をある程度まで減少させる、または最小化することができる。軟らかい口腔組織には、頬粘膜、他の口腔粘膜(例えば、軟口蓋粘膜、口腔底粘膜および舌下粘膜)および舌が含まれる。したがって、本明細書において、非細胞毒性および/または非刺激性の方法で、二酸化塩素組成物を投与することによって、口腔組織感染症を緩和する方法を提供する。
一態様では、本方法は、二酸化塩素を含む実質的に非細胞毒性および/または非刺激性の組成物を投与することを含む。ある実施形態では、組成物は、本質的に、医薬品原料(API)としての二酸化塩素からなる。他の実施形態では、組成物は、二酸化塩素、および抗生物質などの少なくとも1つの他のAPIを含む。組成物は、1つまたは複数の他の成分を任意選択で含む。このような成分には、甘味料、風味料、着色料、および香料が含まれるが、それだけに限定されない。他の任意選択の成分には、抗細菌薬および抗真菌薬などの抗菌薬、酵素、悪臭抑制剤、リン酸塩などの洗浄剤、抗歯肉炎薬、抗歯垢薬、抗歯石薬、フッ化物イオン源などの抗う蝕薬、抗歯周炎薬、栄養剤、酸化防止剤などが含まれる。代表的な抗菌薬には、ドキシサイクリン、メトロニダゾール、クロルヘキシジン、ミノサイクリンおよびテトラサイクリンが含まれるが、それだけに限定されない。代表的な抗真菌薬には、ミコナゾール、ニスタチンおよびアムホテリシンが含まれるが、それだけに限定されない。
別の態様では、本方法は、実質的にオキシ塩素アニオンを含まない二酸化塩素組成物を口腔組織へ送達するデバイスまたは組成物を使用して実施する。二酸化塩素が有効量標的組織に到達するが、オキシ塩素アニオンが標的組織または処置のための標的にされていない周辺組織を刺激するのを実質的に阻害する方法で、二酸化塩素およびオキシ塩素アニオンを含む組成物を投与するためのこのようなデバイス、組成物、システムおよび方法は、「Methods, Systems and Devices for Administration of Chlorine Dioxide」と題された2009年6月15日出願の、本発明の譲受人に譲渡された米国仮特許出願第61/187198号に記載されている。一般的に、本方法は、二酸化塩素自体または二酸化塩素生成成分のいずれかを含み、組織への細胞毒性を引き起こすオキシ塩素アニオンをさらに含む二酸化塩素源を提供することと、実質的にオキシ塩素アニオンがそこを通過するのを禁じ、二酸化塩素がそこを通過するのを許すオキシ塩素アニオン障壁をさらに提供することと、を含む。いくつかの実施形態では、オキシ塩素アニオン障壁は、陽子がそこを通過するのを実質的に阻害することもできる。二酸化塩素源は、オキシ塩素アニオン障壁が二酸化塩素源と組織との間に挿入された状態で組織に適用され、したがって、オキシ塩素アニオンが組織に到達するのを妨げる、または実質的に最小化し、それによって実質的にオキシ塩素アニオンを含まない二酸化塩素組成物を組織へ送達することが可能になる。
二酸化塩素生成成分は、少なくともオキシ塩素アニオン源および二酸化塩素生成の活性剤をさす。いくつかの実施形態では、活性剤は酸性源である。これらの実施形態では、成分は、遊離ハロゲン源を任意選択でさらに含む。遊離ハロゲン源は、塩素などのカチオン性ハロゲン源であってもよい。他の実施形態では、活性剤は、エネルギー活性化可能触媒である。さらに他の実施形態では、活性剤は、乾燥または無水の極性物質である。
組成物の投与量は、広範囲の限度内で変化し、各々個別の場合の個々の必要条件に適合させ得る。投与量は、処置条件、受容者の一般的な健康状態、投与の数および頻度、ならびに当業者に既知の他の変数に依存する。したがって、口腔組織へ送達される二酸化塩素の量(すなわち、有効量)は、二酸化塩素の組織への適用から意図される結果に関連するだろう。当業者は、所与の使用に有効である二酸化塩素の適当な量または量の範囲を容易に決定することができる。一般的に、有用な量は、例えば、二酸化塩素約1〜約2000ppm、少なくとも約1〜約1000ppm、または少なくとも約20〜約400ppmを含む。いくつかの実施形態では、二酸化塩素は、組成物中に少なくとも約5ppm、少なくとも約20ppm、または少なくとも約30ppm存在する。一般的に、二酸化塩素の量は、約1000ppm、約700ppmまで、約500ppmまで、および約200ppmまでに及ぶことができる。一実施形態では、組成物は、約30〜約100ppmの二酸化塩素を含む。いくつかの実施形態では、有用な投与量の範囲は、接触面積(平方メートル)当たり二酸化塩素約2.5mg〜二酸化塩素約500mg/m2とすることができる。少なくとも約10mg/m2、少なくとも約15mg/m2、および少なくとも約20mg/m2の投与量も有用とすることができる。
Claims (27)
- 口腔内の組織の感染症を緩和する方法であって、
二酸化塩素または二酸化塩素生成成分を含む二酸化塩素源を含む組成物を前記口腔に投与して、それによって前記口腔内の組織の感染症を緩和することを含み、
前記投与ステップが、
i)前記組織と、前記二酸化塩素源を含む実質的に非細胞毒性の組成物を接触させる工程、
ii)前記組織と、前記二酸化塩素源およびオキシ塩素アニオンを含むデバイスを接触させる工程(前記デバイスは実質的にオキシ塩素アニオンを含まない二酸化塩素組成物を前記組織へ送達する)を含み、または
iii)前記組織と、前記二酸化塩素源およびオキシ塩素アニオン、ならびに実質的に前記オキシ塩素アニオンの通過を妨げ、実質的にオキシ塩素アニオンを含まない二酸化塩素組成物を通過させ、それによって前記実質的にオキシ塩素アニオンを含まない二酸化塩素組成物の組織への送達を可能にする障壁物質を含む組成物を接触させる工程、
の1又は複数の工程を含む方法。 - 前記組成物が、約1〜約1000ppmの二酸化塩素を含む請求項1に記載の方法。
- 前記組成物が、約20〜約400ppmの二酸化塩素を含む請求項1に記載の方法。
- 前記二酸化塩素源が、前記二酸化塩素生成成分として、二酸化塩素の粒子状前駆物質を含む請求項1に記載の方法。
- 前記口腔組織感染症が、口臭、歯肉炎、歯周炎、う蝕発生および鵞口瘡からなる群から選択される請求項1に記載の方法。
- 前記組成物が抗菌薬をさらに含む請求項1に記載の方法。
- 前記抗菌薬が、ドキシサイクリン、メトロニダゾール、クロルヘキシジン、ミノサイクリン、テトラサイクリン、ニスタチン、ミコナゾールおよびアムホテリシンからなる群から選択される請求項6に記載の方法。
- 抗菌薬を含む第2組成物を前記口腔に投与することをさらに含む請求項1に記載の方法。
- 前記投与ステップが、前記組織と、前記二酸化塩素源を含む実質的に非細胞毒性の組成物を接触させる工程を含む請求項1に記載の方法。
- 前記組成物が、1グラムの組成物当たり約0.2ミリグラム未満のオキシ塩素アニオンを含む請求項9に記載の方法。
- 前記組成物が、約4.5〜約11のpHを有する請求項9に記載の方法。
- 前記接触工程が、デンタルストリップ、デンタルフィルムまたはデンタルトレーを含む請求項9に記載の方法。
- 前記投与ステップが、前記組織と、二酸化塩素源およびオキシ塩素アニオンを含むデバイスを接触させる工程(前記デバイスは実質的にオキシ塩素アニオンを含まない二酸化塩素組成物を前記組織へ送達する)を含む請求項1に記載の方法。
- 前記デバイスが、
任意選択の裏張り層と、
前記二酸化塩素源を含む層と、
前記二酸化塩素源層と前記組織との間に挿入された障壁層と
を備え、
前記障壁層が、実質的に前記オキシ塩素アニオンの通過を妨げ、前記実質的にオキシ塩素アニオンを含まない二酸化塩素組成物を通過させる請求項13に記載の方法。 - 前記障壁層が、ポリウレタン、ポリプロピレン、ポリテトラフルオロエチレン、ポリビニリデンジフルオリド、ポリビニリデンジクロリド、ポリジメチルシロキサンおよびポリテトラフルオロエチレンの組み合わせ、ポリスチレン、酢酸セルロース、ポリシロキサン、ならびにこれらの組み合わせからなる群から選択されるフィルムである請求項14に記載の方法。
- 前記デバイスが、裏張り層および前記裏張り層に貼り付けられたマトリックスを備え、
前記マトリックスが、二酸化塩素源およびオキシ塩素アニオン、ならびに
実質的に前記オキシ塩素アニオンの通過を妨げ、前記実質的にオキシ塩素アニオンを含まない二酸化塩素組成物を通過させる障壁物質、
を含む請求項13に記載の方法。 - 前記障壁物質が、ポリウレタン、ポリプロピレン、ポリテトラフルオロエチレン、ポリビニリデンジフルオリド、ポリビニリデンジクロリド、ポリジメチルシロキサンおよびポリテトラフルオロエチレンの組み合わせ、ポリスチレン、酢酸セルロース、ポリシロキサン、ポリエチレンオキシド、ポリアクリレート、鉱油、パラフィン蝋、ポリイソブチレン、ポリブテン、ならびにこれらの組み合わせからなる群から選択される請求項16に記載のデバイス。
- 前記投与ステップが、前記組織と、二酸化塩素源、オキシ塩素アニオンおよび障壁物質を含む組成物を接触させることを含む請求項1に記載の方法。
- 前記障壁物質が、ポリウレタン、ポリプロピレン、ポリテトラフルオロエチレン、ポリビニリデンジフルオリド、ポリビニリデンジクロリド、ポリジメチルシロキサンおよびポリテトラフルオロエチレンの組み合わせ、ポリスチレン、酢酸セルロース、ポリシロキサン、ポリエチレンオキシド、ポリアクリレート、鉱油、パラフィン蝋、ポリイソブチレン、ポリブテン、ならびにこれらの組み合わせからなる群から選択される請求項18に記載の方法。
- 口腔内の組織の感染症を緩和する方法であって、二酸化塩素源を含む組成物を前記口腔に投与することを含み、前記投与ステップが、前記組織と、前記二酸化塩素源を含む実質的に非刺激性の組成物を接触させる工程を含み、それによって前記口腔内の前記組織の前記感染症を緩和する方法。
- 前記組成物が、約1〜約1000ppmの二酸化塩素を含む、請求項20に記載の方法。
- 前記組成物が、約20〜約400ppmの二酸化塩素を含む、請求項20に記載の方法。
- 前記二酸化塩素源が、二酸化塩素生成成分として、二酸化塩素の粒子状前駆物質を含む、請求項20に記載の方法。
- 前記組成物が、1グラムの組成物当たり約0.2ミリグラム未満のオキシ塩素アニオンを含む、請求項20に記載の方法。
- 前記組成物が、約4.5〜約11のpHを有する、請求項20に記載の方法。
- 前記口腔組織感染症が、口臭、歯肉炎、歯周炎、う蝕発生および鵞口瘡からなる群から選択される、請求項20に記載の方法。
- 前記接触工程が、デンタルストリップ、デンタルフィルムまたはデンタルトレーを含む、請求項20に記載の方法。
Applications Claiming Priority (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13501108P | 2008-07-15 | 2008-07-15 | |
US61/135,011 | 2008-07-15 | ||
US10602608P | 2008-10-16 | 2008-10-16 | |
US61/106,026 | 2008-10-16 | ||
US15068509P | 2009-02-06 | 2009-02-06 | |
US61/150,685 | 2009-02-06 | ||
US18719809P | 2009-06-15 | 2009-06-15 | |
US61/187,198 | 2009-06-15 | ||
US12/502,913 | 2009-07-14 | ||
US12/502,913 US8293283B2 (en) | 2008-07-15 | 2009-07-14 | Methods for treating oral cavity infections with chlorine dioxide |
PCT/US2009/050641 WO2010009200A2 (en) | 2008-07-15 | 2009-07-15 | Methods for treating oral cavity infections with chlorine dioxide |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2011528367A true JP2011528367A (ja) | 2011-11-17 |
Family
ID=41168773
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011518844A Pending JP2011528361A (ja) | 2008-07-15 | 2009-07-14 | 二酸化塩素の投与のための方法、システムおよび機器 |
JP2011518869A Pending JP2011528367A (ja) | 2008-07-15 | 2009-07-15 | 二酸化塩素により口腔感染症を治療する方法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011518844A Pending JP2011528361A (ja) | 2008-07-15 | 2009-07-14 | 二酸化塩素の投与のための方法、システムおよび機器 |
Country Status (12)
Country | Link |
---|---|
US (4) | US20100062042A1 (ja) |
EP (2) | EP2313064A2 (ja) |
JP (2) | JP2011528361A (ja) |
KR (2) | KR20110039461A (ja) |
CN (2) | CN102149363A (ja) |
AR (2) | AR072566A1 (ja) |
BR (2) | BRPI0916446A2 (ja) |
CA (2) | CA2730756A1 (ja) |
CL (2) | CL2009001579A1 (ja) |
MX (2) | MX2011000540A (ja) |
TW (2) | TW201016247A (ja) |
WO (2) | WO2010009140A2 (ja) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8926951B2 (en) * | 2007-07-09 | 2015-01-06 | Micropure, Inc. | Composition for preventing oral disease by penetrating polymicrobial oral biofilms and killing oral pathogens |
KR20110039461A (ko) * | 2008-07-15 | 2011-04-18 | 바스프 코포레이션 | 이산화염소 투여를 위한 방법, 시스템 및 장치 |
US20100196512A1 (en) * | 2009-02-04 | 2010-08-05 | Basf Catalyst Llc | Treatment of Non-Oral Biological Tissue with Chlorine Dioxide |
US20100233101A1 (en) | 2009-02-13 | 2010-09-16 | Micropure, Inc. | Composition and method for the oxidative consumption of salivary biomolecules |
US9101562B2 (en) | 2010-01-31 | 2015-08-11 | Basf Corporation | Additives for chlorine dioxide-containing compositions |
CN103040860B (zh) * | 2012-11-29 | 2018-08-14 | 刘学武 | 一种启动哺乳动物干细胞的方法及二氧化氯在制备用于启动哺乳动物干细胞的药物的应用 |
US9711744B2 (en) | 2012-12-21 | 2017-07-18 | 3M Innovative Properties Company | Patterned structured transfer tape |
US9745820B2 (en) * | 2015-04-28 | 2017-08-29 | Thru Tubing Solutions, Inc. | Plugging device deployment in subterranean wells |
KR20180034505A (ko) * | 2015-07-22 | 2018-04-04 | 카오 그룹, 인코포레이티드 | 혼합되지 않은 반응제 성분들을 포함한 구강 치료용 필름 |
JP7036360B2 (ja) * | 2017-08-30 | 2022-03-15 | 岡山県 | 次亜塩素酸流体の製造方法 |
CA3020197A1 (en) | 2017-09-01 | 2019-03-01 | Micropure, Inc. | Aliphatic anionic compounds and oxidative compounds with improved stability and efficacy for use in pharmaceutical compositions |
MX2021001488A (es) * | 2018-08-10 | 2021-04-28 | Colgate Palmolive Co | Composiciones blanqueadoras y metodos para las mismas. |
CN117401649B (zh) * | 2023-12-15 | 2024-03-08 | 山东华实药业有限公司 | 纯净免活化稳定性二氧化氯溶液 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4788053A (en) * | 1984-07-30 | 1988-11-29 | Ratcliff Perry A | Method and composition for prevention and treatment of oral disease |
JP2001522773A (ja) * | 1997-11-07 | 2001-11-20 | エンゲルハード・コーポレーシヨン | 二酸化塩素を含有する水溶液を製造するための方法および装置 |
WO2006123234A1 (en) * | 2005-05-19 | 2006-11-23 | Mcneil-Ppc, Inc. | Oral care compositions having improved substantivity |
WO2007089473A2 (en) * | 2006-01-26 | 2007-08-09 | Basf Catalysts Llc | Thickened fluid composition comprising chlorine dioxide |
WO2008005548A2 (en) * | 2006-07-07 | 2008-01-10 | The Procter & Gamble Company | Flavors for oral compositions |
Family Cites Families (130)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2071091A (en) * | 1936-07-13 | 1937-02-16 | Mathieson Alkali Works Inc | Chemical manufacture |
CA962021A (en) * | 1970-05-21 | 1975-02-04 | Robert W. Gore | Porous products and process therefor |
US4060600A (en) * | 1972-10-26 | 1977-11-29 | National Patent Development Corporation | Treating teeth |
GB1579431A (en) * | 1976-03-23 | 1980-11-19 | Minnesota Mining & Mfg | Disinfecting and/or sterilising |
US4330531A (en) * | 1976-03-26 | 1982-05-18 | Howard Alliger | Germ-killing materials |
JPS60105610A (ja) | 1983-11-14 | 1985-06-11 | Mitsuru Tsuchikura | 口中歯磨剤に添加する安定化二酸化塩素剤 |
US4671972A (en) * | 1984-03-16 | 1987-06-09 | Warner-Lambert Company | Controlled release encapsulated hypochlorite deactivator for use in denture cleansers |
US4585482A (en) * | 1984-05-25 | 1986-04-29 | Southern Research Institute | Long-acting biocidal compositions and method therefor |
US4696811A (en) * | 1984-07-30 | 1987-09-29 | Ratcliff Perry A | Method and composition for prevention and treatment of oral disease |
US4855135A (en) * | 1984-07-30 | 1989-08-08 | Ratcliff Perry A | Method for debriding |
US4975285A (en) * | 1984-07-30 | 1990-12-04 | Ratcliff Perry A | Method for cleaning dental prosthetic devices |
US4818519A (en) * | 1986-12-29 | 1989-04-04 | Ratcliff Perry A | Method and composition for prevention of plaque formation and plaque dependent diseases |
US4886657A (en) * | 1984-07-30 | 1989-12-12 | Ratcliff Perry A | Method for preventing periodontitis |
US4889714A (en) * | 1984-07-30 | 1989-12-26 | Ratcliff Perry A | Method for retarding dental plaque by killing streptococcus sanguis |
US4793989A (en) * | 1984-07-30 | 1988-12-27 | Ratcliff Perry A | Method and composition for prevention and treatment of oral disease |
US4837009A (en) * | 1986-03-31 | 1989-06-06 | Ratcliff Perry A | Method and composition for prevention of plaque formation and plaque dependent diseases |
US4689215A (en) * | 1984-07-30 | 1987-08-25 | Ratcliff Perry A | Method and composition for prevention and treatment of oral disease |
US4828857A (en) * | 1984-10-05 | 1989-05-09 | Warner-Lambert Company | Novel sweetener delivery systems |
US4683039A (en) * | 1985-12-24 | 1987-07-28 | Tenneco Canada Inc. (Erco Division) | Membrane pervaporation process |
US4851213A (en) * | 1986-03-31 | 1989-07-25 | Ratcliff Perry A | Method and composition for prevention and treatment of oral disease due to S. Sanguis |
US4792442A (en) * | 1986-03-31 | 1988-12-20 | Ratcliff Perry A | Method and composition for prevention and treatment of oral disease |
US4925656A (en) * | 1986-03-31 | 1990-05-15 | Ratcliff Perry A | Method for retarding formation of dental plaque |
US4786492A (en) * | 1986-03-31 | 1988-11-22 | Ratcliff Perry A | Method and composition for prevention and treatment of oral disease |
US5200171A (en) * | 1990-11-20 | 1993-04-06 | Micropure, Inc. | Oral health preparation and method |
US4808389A (en) * | 1986-12-29 | 1989-02-28 | Ratcliff Perry A | Method and composition for prevention and treatment of oral disease |
US5348734A (en) * | 1990-11-20 | 1994-09-20 | Micropure Inc. | Oral health preparation and method |
US4945125A (en) * | 1987-01-05 | 1990-07-31 | Tetratec Corporation | Process of producing a fibrillated semi-interpenetrating polymer network of polytetrafluoroethylene and silicone elastomer and shaped products thereof |
US4865848A (en) * | 1987-02-26 | 1989-09-12 | Alza Corporation | Skin permeation enhancer compositions using sucrose esters |
US4832009A (en) * | 1987-12-23 | 1989-05-23 | Bio Med Sciences, Inc. | Semi-interpenetrating network polymer backsheet bandage |
US4956184A (en) * | 1988-05-06 | 1990-09-11 | Alcide Corporation | Topical treatment of genital herpes lesions |
US5227168A (en) * | 1989-11-21 | 1993-07-13 | Bruce Barber | Method of treating a wound |
US5281412A (en) * | 1991-12-30 | 1994-01-25 | The Procter & Gamble Company | Oral compositions |
US5407656A (en) * | 1992-03-04 | 1995-04-18 | Arco Research Co., Inc. | Method and compositions for the production of chlorine dioxide |
US5719100A (en) * | 1992-03-20 | 1998-02-17 | Zahradnik; Rudolf | Water treatment compositions |
GB9206244D0 (en) * | 1992-03-23 | 1992-05-06 | Pharma Mar Sa | Cytotoxic compound from a marine sponge |
IL102627A (en) * | 1992-07-23 | 1996-05-14 | Abic Ltd | Solid composition releasing chlorine dioxide |
US6046243A (en) * | 1993-02-12 | 2000-04-04 | Bernard Technologies, Inc. | Compositions for sustained release of a gas |
US5736165A (en) * | 1993-05-25 | 1998-04-07 | Allergan | In-the-eye use of chlorine dioxide-containing compositions |
US6200557B1 (en) * | 1993-07-06 | 2001-03-13 | Perry A. Ratcliff | Method of treating HIV by a topical composition |
US5489435A (en) * | 1993-07-06 | 1996-02-06 | Ratcliff; Perry A. | Composition for treatment of abnormal conditions of the epithelium of bodily orifices |
US5526841A (en) * | 1993-08-20 | 1996-06-18 | Detsch; Steven G. | Water line decontamination system |
US5656279A (en) * | 1994-02-23 | 1997-08-12 | Bio Med Sciences, Inc. | Semi-interpenetrating polymer network scar treatment sheeting, process of manufacture and useful articles thereof |
WO1995027472A1 (en) * | 1994-04-07 | 1995-10-19 | Richter Jon L | Oral rinse and method of treating halitosis |
US5597561A (en) * | 1994-12-14 | 1997-01-28 | Alcide Corporation | Adherent disinfecting compositions and methods of use in skin disinfection |
GB2300423A (en) * | 1995-03-27 | 1996-11-06 | Jeyes Group Plc | Lavatory cleansing |
ATE232715T1 (de) * | 1995-09-25 | 2003-03-15 | Robert Eric Montgomery | Zahnbleichende zusammensetzungen |
JP2000516221A (ja) * | 1996-07-29 | 2000-12-05 | モンゴメリー、ロバート・エリック | 二酸化塩素歯白色化組成物 |
US5820822A (en) * | 1996-10-25 | 1998-10-13 | Kross; Robert D. | Antimicrobial composition and method of use |
US6077495A (en) * | 1997-03-03 | 2000-06-20 | Engelhard Corporation | Method, composition and system for the controlled release of chlorine dioxide gas |
US6007735A (en) * | 1997-04-30 | 1999-12-28 | Ecolab Inc. | Coated bleach tablet and method |
US5879691A (en) * | 1997-06-06 | 1999-03-09 | The Procter & Gamble Company | Delivery system for a tooth whitener using a strip of material having low flexural stiffness |
US6096328A (en) * | 1997-06-06 | 2000-08-01 | The Procter & Gamble Company | Delivery system for an oral care substance using a strip of material having low flexural stiffness |
US6630937B2 (en) * | 1997-10-30 | 2003-10-07 | University Of South Florida | Workstation interface for use in digital mammography and associated methods |
US6365131B1 (en) * | 1997-10-31 | 2002-04-02 | J. B. Chemicals & Pharmaceuticals Ltd. | Pharmaceutical dental formulation for topical application of metronidazole benzoate, chlorhexidine gluconate and local anesthetic |
US6077502A (en) * | 1998-02-27 | 2000-06-20 | The Procter & Gamble Company | Oral care compositions comprising chlorite and methods |
US6039934A (en) * | 1998-08-04 | 2000-03-21 | Alliger; Howard | Use of xanthan gum for gelling CIO2 and related species |
DE19854349A1 (de) | 1998-11-25 | 2000-05-31 | Up To Dent Ag Balzers | Mundpflegemittel |
US6106284A (en) * | 1999-01-15 | 2000-08-22 | Cronin; Richard J. | Dental cast tray assembly |
US7273567B1 (en) * | 1999-11-24 | 2007-09-25 | Microactive Corp. | Energy-activated compositions for controlled sustained release of a gas |
US6280775B1 (en) * | 1999-06-09 | 2001-08-28 | Joseph Alan Sasson | Antimicrobial oral composition and method of use |
ATE238766T1 (de) * | 1999-07-02 | 2003-05-15 | Procter & Gamble | Zusammensetzungen zur freisetzung von mundpflegewirkstoffen enthaltend organosiloxan harze durch verwendung eines wiederablösbaren trägerstreifens |
US7384650B2 (en) * | 1999-11-24 | 2008-06-10 | Agile Therapeutics, Inc. | Skin permeation enhancement composition for transdermal hormone delivery system |
US6379658B1 (en) * | 1999-12-21 | 2002-04-30 | International Flavors & Fragrances Inc. | Human sweat malodor counteractant composition and process for using same |
US20060169949A1 (en) * | 2000-02-02 | 2006-08-03 | Speronello Barry K | Massive bodies containing free halogen source for producing highly converted thickened solutions of chlorine dioxide |
US6432322B1 (en) * | 2000-02-02 | 2002-08-13 | Engelhard Corporation | Massive bodies for producing highly converted solutions of chlorine dioxde |
ES2320321T3 (es) * | 2000-03-17 | 2009-05-21 | LG HOUSEHOLD & HEALTH CARE LTD. | Parches para blanquear dientes. |
US6432387B1 (en) * | 2000-03-23 | 2002-08-13 | Create Co., Ltd. | Ionic tooth polishing agent |
US6582682B2 (en) * | 2000-10-30 | 2003-06-24 | Noville, Inc. | Oral care compositions comprising stabilized chlorine dioxide |
US6425759B1 (en) * | 2000-11-15 | 2002-07-30 | Richard J. Cronin | Dental cast tray assembly |
AU2002240115B2 (en) * | 2001-01-24 | 2007-01-04 | Discus Dental, Llc. | Topical oral care compositions |
US6500408B2 (en) * | 2001-01-27 | 2002-12-31 | Jc Technologies, Inc. | Enamel-safe tooth bleach and method for use |
US6514484B2 (en) * | 2001-03-19 | 2003-02-04 | The Procter & Gamble Company | Systems for delivering a cosmetic and/or therapeutic active to oral surfaces using an integral carrier |
US6669931B2 (en) * | 2001-03-29 | 2003-12-30 | Curozone Ireland Limited | Formulation for the remineralization of teeth |
US20030235549A1 (en) * | 2001-05-01 | 2003-12-25 | Parminder Singh | Hydrogel compositions demonstrating phase separation on contact with aqueous media |
US8840918B2 (en) * | 2001-05-01 | 2014-09-23 | A. V. Topchiev Institute of Petrochemical Synthesis, Russian Academy of Sciences | Hydrogel compositions for tooth whitening |
US7087208B2 (en) * | 2001-08-02 | 2006-08-08 | Sampson Allison H | Methods for making chlorous acid and chlorine dioxide |
US6759030B2 (en) * | 2002-03-21 | 2004-07-06 | Carl M. Kosti | Bleach stable toothpaste |
AU2003301240A1 (en) * | 2002-05-20 | 2004-05-04 | William O. Kling | Skin cleanser compositions and methods of use |
US20030228264A1 (en) * | 2002-06-06 | 2003-12-11 | Perna Salvatore F. | Dissolvable teeth whitening apparatus |
US6896518B2 (en) * | 2002-06-28 | 2005-05-24 | Scott Jacobs | Teeth treatment device |
US7029705B2 (en) * | 2002-07-30 | 2006-04-18 | Fuhr Allan H | Nasal hygiene method and composition |
US6848905B2 (en) * | 2002-08-20 | 2005-02-01 | Archtek, Inc. | Method of making a dental tray using a patient's teeth as a template |
US6881061B2 (en) * | 2002-09-30 | 2005-04-19 | Mcneil-Ppc, Inc. | Ultrasonic method for cleaning teeth |
US7004756B2 (en) * | 2003-01-24 | 2006-02-28 | Ultradent Products, Inc. | Pre-shaped dental trays and treatment devices and methods that utilize such dental trays |
US6964571B2 (en) * | 2003-01-24 | 2005-11-15 | Ultradent Products, Inc. | Pre-shaped dental trays and treatment devices and methods that utilize such dental trays |
US7087190B2 (en) * | 2003-03-20 | 2006-08-08 | Ecolab Inc. | Composition for the production of chlorine dioxide using non-iodo interhalides or polyhalides and methods of making and using the same |
US7252096B2 (en) * | 2003-04-08 | 2007-08-07 | Nalco Company | Methods of simultaneously cleaning and disinfecting industrial water systems |
US7040897B2 (en) * | 2003-05-23 | 2006-05-09 | Ultradent Products, Inc. | Thin, flexible membrane dental trays and systems and methods utilizing such trays |
US8137581B2 (en) * | 2003-08-04 | 2012-03-20 | Basf Corporation | Chlorine dioxide releasing composite article |
US7229647B2 (en) * | 2003-10-09 | 2007-06-12 | Sunggyu Lee | Chlorine dioxide gel and associated methods |
US20060183080A1 (en) * | 2003-11-21 | 2006-08-17 | Vasiliy Nosov | Dental treatment kits and methods for forming customized dental trays |
US20050137109A1 (en) * | 2003-12-17 | 2005-06-23 | The Procter & Gamble Company | Emulsion composition for delivery of bleaching agents to teeth |
US7059858B2 (en) * | 2004-02-19 | 2006-06-13 | Ultradent Products, Inc. | Universal tray design having anatomical features to enhance fit |
US7044737B2 (en) * | 2004-03-05 | 2006-05-16 | Liang Fu | Ultrasound oral hygiene and therapeutic device |
US7383946B2 (en) * | 2004-03-26 | 2008-06-10 | Hughes Kenneth D | Materials for storing and releasing reactive gases |
US20060006361A1 (en) * | 2004-07-08 | 2006-01-12 | Joseph Callerame | Clathrate of chlorine dioxide |
US20060045855A1 (en) * | 2004-09-02 | 2006-03-02 | Sasson J A | Oral composition for reducing plaque and microbial infections and whitening teeth |
US7497834B2 (en) * | 2004-10-22 | 2009-03-03 | General Patent Llc | Germicidal method for eradicating or preventing the formation of biofilms |
US20060088498A1 (en) * | 2004-10-27 | 2006-04-27 | Truox, Inc. | Anti-microbial composition using in-situ generation of an oxidizing agent |
US20060099550A1 (en) * | 2004-11-10 | 2006-05-11 | Ranir/Dcp Corporation | Device and method for delivering an oral care agent |
US7534368B2 (en) * | 2005-03-01 | 2009-05-19 | Truox, Inc. | Oxidizing composition including a gel layer |
US7514019B2 (en) * | 2005-03-01 | 2009-04-07 | Truox, Inc. | Solvent-activated reactor including a gel layer |
US8753612B2 (en) * | 2005-04-11 | 2014-06-17 | Sylphar Nv | Foam strip for the delivery of oral care compositions |
US20080209650A1 (en) * | 2005-05-03 | 2008-09-04 | Ultreo, Inc. | Oral hygiene devices |
US20060292090A1 (en) * | 2005-06-22 | 2006-12-28 | Deepak Sharma | Oral care compositions, devices, and methods of using the same |
US20060292092A1 (en) * | 2005-06-22 | 2006-12-28 | Deepak Sharma | Oral care compositions, devices, and methods of using the same |
CA2629888C (en) | 2005-11-14 | 2017-02-14 | Cdg Technology Inc. | Storage-stable aqueous solutions of chlorine dioxide and methods for preparing and using them |
CN101360464B (zh) | 2005-11-22 | 2012-02-08 | 史密丝克莱恩比彻姆公司 | 泡沫基质及其制备方法 |
WO2008048350A2 (en) * | 2006-02-24 | 2008-04-24 | Nanovibronix Inc. | System and method for surface acoustic wave treatment of skin |
US8673297B2 (en) * | 2006-02-28 | 2014-03-18 | Basf Corporation | Chlorine dioxide based cleaner/sanitizer |
US20070231277A1 (en) * | 2006-03-31 | 2007-10-04 | Deepak Sharma | Multicomponent whitening compositions and containers |
GB0609485D0 (en) | 2006-05-12 | 2006-06-21 | Glaxo Group Ltd | Chlorine dioxide tooth whitening composition |
US20070298380A1 (en) * | 2006-06-26 | 2007-12-27 | Ultradent Products, Inc. | Dental treatment devices adapted for improved lingual side adhesion |
US20080020064A1 (en) * | 2006-07-21 | 2008-01-24 | Advanced Vision Research | Methods and compositions for the treatment of infection or infectious colonization of the eyelid, ocular surface, skin or ear |
US9067082B2 (en) * | 2006-07-26 | 2015-06-30 | Ultradent Products, Inc. | Dental bleaching compositions having long-term rheological stability and devices, kits and methods that utilize such compositions |
US20080041400A1 (en) * | 2006-08-17 | 2008-02-21 | Darnell Daniel H | System and Process for Custom Molding Dental Trays |
US20100030132A1 (en) * | 2006-09-28 | 2010-02-04 | Jeffrey Niezgoda | Apparatus and method for wound, cavity, and bone treatment |
WO2008052198A2 (en) * | 2006-10-26 | 2008-05-02 | Reliant Technologies, Inc. | Methods of increasing skin permeability by treatment with electromagnetic radiation |
CN101547898B (zh) * | 2006-12-10 | 2014-09-24 | 于崇曦 | β-内酰胺类抗生素的透皮给药系统 |
US7875460B2 (en) * | 2007-07-09 | 2011-01-25 | Micropure, Inc. | Method for determining the effectiveness of stabilized chlorine dioxide in a mouth rinse |
US8926951B2 (en) * | 2007-07-09 | 2015-01-06 | Micropure, Inc. | Composition for preventing oral disease by penetrating polymicrobial oral biofilms and killing oral pathogens |
US20090016973A1 (en) * | 2007-07-09 | 2009-01-15 | Micropure, Inc. | Composition and Method for the Prevention of Oral Disease |
US9320921B2 (en) * | 2008-12-22 | 2016-04-26 | Karen C. Swenholt | Nail fungus treatment and composition |
US20100009009A1 (en) * | 2008-07-10 | 2010-01-14 | Micropure, Inc. | Method and composition for prevention and treatment of oral fungal infections |
US20100012892A1 (en) * | 2008-07-15 | 2010-01-21 | Basf Catalysts Llc | Tooth Whitening Compositions and Methods |
KR20110039461A (ko) * | 2008-07-15 | 2011-04-18 | 바스프 코포레이션 | 이산화염소 투여를 위한 방법, 시스템 및 장치 |
US8697141B2 (en) * | 2008-08-26 | 2014-04-15 | Micropure, Inc. | Method and composition for preventing and healing osteonecrosis of the jaw |
GB2478478C (en) | 2008-12-22 | 2020-03-04 | Micropure Inc | Composition and method for reducing demineralization of teeth |
US20100196512A1 (en) * | 2009-02-04 | 2010-08-05 | Basf Catalyst Llc | Treatment of Non-Oral Biological Tissue with Chlorine Dioxide |
US20100233101A1 (en) * | 2009-02-13 | 2010-09-16 | Micropure, Inc. | Composition and method for the oxidative consumption of salivary biomolecules |
-
2009
- 2009-07-14 KR KR1020117003404A patent/KR20110039461A/ko not_active Application Discontinuation
- 2009-07-14 BR BRPI0916446A patent/BRPI0916446A2/pt not_active IP Right Cessation
- 2009-07-14 CA CA2730756A patent/CA2730756A1/en not_active Abandoned
- 2009-07-14 JP JP2011518844A patent/JP2011528361A/ja active Pending
- 2009-07-14 WO PCT/US2009/050559 patent/WO2010009140A2/en active Application Filing
- 2009-07-14 CN CN2009801356805A patent/CN102149363A/zh active Pending
- 2009-07-14 US US12/502,845 patent/US20100062042A1/en not_active Abandoned
- 2009-07-14 EP EP09790402A patent/EP2313064A2/en not_active Withdrawn
- 2009-07-14 MX MX2011000540A patent/MX2011000540A/es active IP Right Grant
- 2009-07-14 US US12/502,858 patent/US20100062043A1/en not_active Abandoned
- 2009-07-14 CL CL2009001579A patent/CL2009001579A1/es unknown
- 2009-07-14 US US12/502,877 patent/US20100112059A1/en not_active Abandoned
- 2009-07-14 US US12/502,913 patent/US8293283B2/en not_active Expired - Fee Related
- 2009-07-15 BR BRPI0916250A patent/BRPI0916250A2/pt not_active IP Right Cessation
- 2009-07-15 KR KR1020117003405A patent/KR20110042310A/ko not_active Application Discontinuation
- 2009-07-15 CA CA2741231A patent/CA2741231A1/en not_active Abandoned
- 2009-07-15 TW TW098123957A patent/TW201016247A/zh unknown
- 2009-07-15 EP EP09790441A patent/EP2313067A2/en not_active Withdrawn
- 2009-07-15 TW TW098124021A patent/TW201016136A/zh unknown
- 2009-07-15 CL CL2009001600A patent/CL2009001600A1/es unknown
- 2009-07-15 JP JP2011518869A patent/JP2011528367A/ja active Pending
- 2009-07-15 MX MX2011000538A patent/MX2011000538A/es active IP Right Grant
- 2009-07-15 WO PCT/US2009/050641 patent/WO2010009200A2/en active Application Filing
- 2009-07-15 CN CN2009801318080A patent/CN102123694B/zh not_active Expired - Fee Related
- 2009-07-16 AR ARP090102707A patent/AR072566A1/es unknown
- 2009-07-16 AR ARP090102704A patent/AR072516A1/es not_active Application Discontinuation
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4788053A (en) * | 1984-07-30 | 1988-11-29 | Ratcliff Perry A | Method and composition for prevention and treatment of oral disease |
JP2001522773A (ja) * | 1997-11-07 | 2001-11-20 | エンゲルハード・コーポレーシヨン | 二酸化塩素を含有する水溶液を製造するための方法および装置 |
WO2006123234A1 (en) * | 2005-05-19 | 2006-11-23 | Mcneil-Ppc, Inc. | Oral care compositions having improved substantivity |
WO2007089473A2 (en) * | 2006-01-26 | 2007-08-09 | Basf Catalysts Llc | Thickened fluid composition comprising chlorine dioxide |
WO2008005548A2 (en) * | 2006-07-07 | 2008-01-10 | The Procter & Gamble Company | Flavors for oral compositions |
Non-Patent Citations (2)
Title |
---|
JPN6013053655; 口腔衛生学会雑誌 56巻4号, 2006, 565ページ P-84 * |
JPN6013053656; 口腔衛生学会雑誌 55巻4号, 2005, 376ページ P1-B-06 * |
Also Published As
Publication number | Publication date |
---|---|
CA2730756A1 (en) | 2010-01-21 |
KR20110042310A (ko) | 2011-04-26 |
MX2011000540A (es) | 2011-08-17 |
WO2010009140A3 (en) | 2010-04-01 |
BRPI0916446A2 (pt) | 2018-09-11 |
CA2741231A1 (en) | 2010-01-21 |
JP2011528361A (ja) | 2011-11-17 |
US8293283B2 (en) | 2012-10-23 |
BRPI0916250A2 (pt) | 2015-11-03 |
US20100062042A1 (en) | 2010-03-11 |
TW201016247A (en) | 2010-05-01 |
AR072516A1 (es) | 2010-09-01 |
EP2313064A2 (en) | 2011-04-27 |
EP2313067A2 (en) | 2011-04-27 |
MX2011000538A (es) | 2011-08-12 |
CL2009001600A1 (es) | 2012-02-10 |
TW201016136A (en) | 2010-05-01 |
WO2010009200A2 (en) | 2010-01-21 |
WO2010009140A2 (en) | 2010-01-21 |
WO2010009200A3 (en) | 2010-03-11 |
KR20110039461A (ko) | 2011-04-18 |
CN102123694A (zh) | 2011-07-13 |
US20100015207A1 (en) | 2010-01-21 |
US20100062043A1 (en) | 2010-03-11 |
CL2009001579A1 (es) | 2011-07-22 |
CN102149363A (zh) | 2011-08-10 |
AR072566A1 (es) | 2010-09-08 |
CN102123694B (zh) | 2013-07-31 |
US20100112059A1 (en) | 2010-05-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8293283B2 (en) | Methods for treating oral cavity infections with chlorine dioxide | |
TWI466635B (zh) | 不具細胞毒性之二氧化氯流體 | |
KR20110116202A (ko) | 이산화염소를 이용한 비-구강 생물학적 조직의 치료 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120712 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20131029 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140127 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140203 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140228 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140305 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140307 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20141125 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20150421 |